All times are listed in CEST (Central European Summer Time)

Displaying One Session

Industry Satellite Symposium

Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification

Date
14.09.2020
Chairs
  • Nicolas Mottet (Saint-Étienne, cédex 2, France)
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

Welcome and introduction (ID 5394)

Speakers
  • Nicolas Mottet (Saint-Étienne, cédex 2, France)
Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

The need and importance of treating patients with early treatment intensification (ID 5395)

Speakers
  • Nicolas Mottet (Saint-Étienne, cédex 2, France)
Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

Weighing up the options for patients with mHSPC (ID 5396)

Speakers
  • Christopher Sweeney (Boston, MA, United States of America)
Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

Tailoring treatment to patient needs for high-risk nmCRPC (ID 5397)

Speakers
  • Chirstian Thomas (Dresden, Germany)
Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

What treatment options remain when patients progress to mCRPC? (ID 5399)

Speakers
  • Nicolas Mottet (Saint-Étienne, cédex 2, France)
  • Christopher Sweeney (Boston, MA, United States of America)
  • Chirstian Thomas (Dresden, Germany)
Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

Summary and close (ID 5400)

Speakers
  • Nicolas Mottet (Saint-Étienne, cédex 2, France)
Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification Industry Satellite Symposium

Disclaimer: This symposium is fully sponsored and supported by Astellas, including speaker honoraria and production of materials, and may include promotional messages related to Astellas products. This symposium will contain discussion relating to XTANDI™ (enzalutamide). The content of the symposium is based on the fact that XTANDI (enzalutamide) is licensed for the treatment of adult men in the US for the following indications: Castration-resistant prostate cancer (CRPC); Metastatic castration-sensitive prostate cancer (mCSPC). XTANDI (enzalutamide) is not licensed in the EEA or Switzerland for mCSPC. This indication is, however, approved in the US, Canada, Russia, Japan and Lebanon. All product information discussed in this symposium will include references to the US Prescribing Information, EMA SmPC and Swiss Prescribing Information. Please note that registration requirements and the governmental-approved information for healthcare professionals regarding indications, warnings, etc. may differ in the countries where XTANDI (enzalutamide) is authorised for use in the above-specified indications. All healthcare professionals should refer to their own country specific prescribing information for XTANDI (enzalutamide). (ID 5481)

Session Name
Astellas - Improving advanced prostate cancer patients’ lives with early treatment intensification